Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats
- PMID: 20688733
- DOI: 10.1167/iovs.09-4727
Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats
Abstract
Purpose: To evaluate the protective effect of intravitreal injection of exendin-4 analogue (E4a) in early diabetic retinopathy (DR) and to explore its possible mechanism.
Methods: Forty Sprague-Dawley rats were divided into three groups: normal (N), diabetic (D), and E4a-treated diabetic rats (E4a). Diabetes was induced by streptozotocin. Rats in the E4a group were treated with E4a (0.1 μg/2μL/eye), whereas the N and D groups were treated with the equivalent volume of normal saline. Electroretinography was performed at 1 month and 3 months after diabetes onset. Thicknesses and cell counts in each layer of the retina were evaluated. The concentration of glutamate was measured by high-performance liquid chromatography (HPLC). Expressions of glucagon-like peptide-1 receptor (GLP-1R) and GLAST (excitatory amino acid transporter) were detected at mRNA and protein levels and verified by immunohistochemistry in vitro and in vivo. The rMc-1 cells were cultured under high-glucose medium (25 mM), which mimicked diabetic conditions. Effects of E4a (10 μg/mL) were also tested in the rMc-1 culture system.
Results: E4a prevented the reduction in b-wave amplitude and oscillatory potential amplitude caused by diabetes. It also prevented the cell loss of outer nuclear layer and inner nuclear layer; the thickness and cell count in the outer nuclear layer were decreased in 1-month diabetic rats. The concentration of glutamate in the retina was higher in diabetic rats and was significantly reduced in the E4a-treated group. Consistent with such changes, retinal GLP-1R and GLAST expression were reduced in the diabetic retina but upregulated in E4a-treated rats. No improvement was found in the retina in both functional and morphologic parameters 3 months after treatment.
Conclusions: Intravitreal administration of E4a can prevent the retina, functionally and morphologically, from the insults of diabetes in rats. GLP-1R and GLAST were proved to exist in the rat retina, and their lowered expressions in the diabetic retina might be related to retinal damage by increasing the retinal glutamate. E4a might protect the retina by reducing the glutamate level through upregulating GLP-1R and GLAST, as observed in retinal Müller cells in this study, but this protective effect was transient. Thus, this could be a potential approach for the treatment of DR.
Similar articles
-
Protection of exendin-4 analogue in early experimental diabetic retinopathy.Graefes Arch Clin Exp Ophthalmol. 2009 May;247(5):699-706. doi: 10.1007/s00417-008-1004-3. Epub 2008 Dec 16. Graefes Arch Clin Exp Ophthalmol. 2009. PMID: 19084986
-
Erythropoietin exerts a neuroprotective function against glutamate neurotoxicity in experimental diabetic retina.Invest Ophthalmol Vis Sci. 2014 Oct 21;55(12):8208-22. doi: 10.1167/iovs.14-14435. Invest Ophthalmol Vis Sci. 2014. PMID: 25335981
-
Intravitreal injection of erythropoietin protects against retinal vascular regression at the early stage of diabetic retinopathy in streptozotocin-induced diabetic rats.Exp Eye Res. 2013 Jan;106:64-73. doi: 10.1016/j.exer.2012.11.001. Epub 2012 Nov 21. Exp Eye Res. 2013. PMID: 23178551
-
The potential benefits of glucagon-like peptide-1 receptor agonists for diabetic retinopathy.Peptides. 2018 Feb;100:123-126. doi: 10.1016/j.peptides.2017.08.003. Epub 2017 Aug 12. Peptides. 2018. PMID: 28807775 Review.
-
[Preretinopathic changes in the oscillatory potential in diabetic retina: interpretation and significance].Nippon Ganka Gakkai Zasshi. 1998 Dec;102(12):813-36. Nippon Ganka Gakkai Zasshi. 1998. PMID: 10025114 Review. Japanese.
Cited by
-
Neuroprotective Peptides in Retinal Disease.J Clin Med. 2019 Aug 1;8(8):1146. doi: 10.3390/jcm8081146. J Clin Med. 2019. PMID: 31374938 Free PMC article. Review.
-
Induction of a Müller Glial Cell-Specific Protective Pathway Safeguards the Retina From Diabetes-Induced Damage.Diabetes. 2025 Jan 1;74(1):96-107. doi: 10.2337/db24-0199. Diabetes. 2025. PMID: 39446557
-
Semaglutide-eye-catching results.World J Diabetes. 2023 Apr 15;14(4):424-434. doi: 10.4239/wjd.v14.i4.424. World J Diabetes. 2023. PMID: 37122431 Free PMC article. Review.
-
Treatment with hydrogen sulfide alleviates streptozotocin-induced diabetic retinopathy in rats.Br J Pharmacol. 2013 Jun;169(3):619-31. doi: 10.1111/bph.12163. Br J Pharmacol. 2013. PMID: 23488985 Free PMC article.
-
Early retinal pigment epithelium dysfunction is concomitant with hyperglycemia in mouse models of type 1 and type 2 diabetes.J Neurophysiol. 2015 Feb 15;113(4):1085-99. doi: 10.1152/jn.00761.2014. Epub 2014 Nov 26. J Neurophysiol. 2015. PMID: 25429122 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical